Antiretroviral drug studies in nonhuman primates: A valid animal model for innovative drug efficacy and pathogenesis experiments

AIDS Reviews

Volumn 7, Issue 2, 2005, Pages 67-83

  Van Rompay, Koen K A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Chemotherapy; Macaque; Monkey; Prophylaxis; Resistance

Indexed keywords

2',3' DIDEOXY 3' HYDROXYMETHYLCYTIDINE; 3' FLUOROTHYMIDINE; ADEFOVIR; ANTIRETROVIRUS AGENT; CD8 ANTIGEN; CHEMOKINE RECEPTOR ANTAGONIST; CHEMOKINE RECEPTOR CCR5; EFAVIRENZ; EMTRICITABINE; GW 420867; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTEGRASE INHIBITOR; L 870812; LAMIVUDINE; NEVIRAPINE; PROTEINASE INHIBITOR; REAGENT; RNA DIRECTED DNA POLYMERASE INHIBITOR; TENOFOVIR; UNCLASSIFIED DRUG; ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL DISEASE; CHIMPANZEE; DISEASE MODEL; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG RESEARCH; FANCONI RENOTUBULAR SYNDROME; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; INFECTION PREVENTION; MACACA; NONHUMAN; PATHOGENESIS; PRIMATE; REVIEW; SIMIAN IMMUNODEFICIENCY VIRUS; VIREMIA; VIRUS ISOLATION; VIRUS MUTANT;

ANIMALS; ANTI-RETROVIRAL AGENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, VIRAL; PRIMATES; REPRODUCIBILITY OF RESULTS; RETROVIRUSES, SIMIAN; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; VIRULENCE;

EID: 23144468115     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (196)

1. De Clercq E. HIV-chemotherapy and -prophylaxis: new drugs, leads and approaches. Int J Biochem Cell Biol 2004;36:1800-22.
2. Sabin C, Hill T, Lampe F, et al. Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study. Br Med J 2005; doi:10.1136/bmj.38369.669850.8F (published 4 March 2005).
3. Van Rompay K, Marthas M. Non-human primate models for testing anti-HIV drugs; In: J. Kreuter, R. Unger and Rüebsamen-Waigmann, editors. Antivirals against AIDS. New York: Marcel Dekker, Inc.; 2000. p. 295-320.
4. Nath B, Schumann K, Boyer J. The chimpanzee and other non-human-primate models in HIV-1 vaccine research. Trends Microbiol 2000;8:426-31.
5. Novembre F, Saucier M, Anderson D, et al. Development of AIDS in a chimpanzee infected with HIV. J Virol 1997;71:4086-91.
6. Silvestri G, Sodora D, Koup R, et al. Nonpathogenic SIV infection of Sooty Mangabeys is characterized by limited bystander immunopathology despite chronic high-level viremia. Immunity 2003;18:1-20.
7. Silvestri G, Fedanov A, Germon S, et al. Divergent host responses during primary simian immunodeficiency virus SIVsm infection of natural sooty mangabey and nonnatural rhesus macaque hosts. J Virol 2005;79:4043-54.
8. Haigwood N. Predictive value of primate models for AIDS. AIDS Rev 2004;6:187-98.
9. Bohm R, Martin L, Davison-Fairburn B, et al. Neonatal disease induced by SIV infection of the rhesus monkey (Macaca mulatta). AIDS Res Hum Retroviruses 1993;9:1131-7.
10. Marthas M, Van Rompay K, Otsyula M, et al. Viral factors determine progression to AIDS in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol 1995;69:4198-205.
11. Carlsson H, Schapiro S, Farah I, et al. Use of primates in research: a global overview. Am J Primatol 2004;63:225-37.
12. Desrosiers R. The simian immunodeficiency viruses. Ann Rev Immunol 1990; 8:557-78.
13. Black P, Downs M, Lewis M, et al. Antiretroviral activities of protease inhibitors against murine leukemia virus and simian immunodeficiency virus in culture. Antimicrob Agents Chemother 1993;37:71-7.
14. Sager P, Cradock J, Litterst C, et al. In vitro testing of therapeutics against SIV and HIV. Ann NY Acad Sci 1990;616:599-605.
15. Giuffre A, Higgins J, Buckheit R, Jr., et al. Susceptibilities of simian immunodeficiency virus to protease inhibitors. Antimicrob Agents Chemother 2003;47:1756-9.
16. Hazuda D, Young S, Guare J, et al. Integrase inhibitors and cellular immunity suppress retroviral replication in rhesus macaques. Science 2004;305:528-32.
17. Veazey R, Klasse P, Ketas T, et al. Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med 2003;198:1551-62.
18. De Clercq E. HIV inhibitors targeted at the reverse transcriptase. AIDS Res Hum Retroviruses 1992;8:119-34.
19. Überla K, Stahl-Hennig C, Böttiger D, et al. Animal model for the therapy of acquired immunodeficiency syndrome with reverse transcriptase inhibitors. Proc Natl Acad Sci USA 1995;92:8210-4.
20. Balzarini J, De Clercq E, Überla K. SIV/HIV-1 hybrid virus expressing the reverse transcriptase gene of HIV-1 remains sensitive to HIV-1-specific reverse transcriptase inhibitors after passage in rhesus macaques. J Acquir Immune Defic Syndr Human Retrovirol 1997;15:1-4.
21. Mori K, Yasumoti Y, Sawada S, et al. Suppression of acute viremia by short-term postexposure prophylaxis of simian/human immunodeficiency virus SHIV-RT-infected monkeys with a novel reverse transcriptase inhibitor (GW420867) allows for development of potent antiviral immune responses resulting in efficient containment of infection. J Virol 2000;74:5747-53.
22. Zuber B, Böttiger D, Benthin R, et al. An in vivo model for HIV resistance development. AIDS Res Hum Retroviruses 2001;17:631-5.
23. Hofman M, Higgins J, Matthews T, et al. Efavirenz therapy in rhesus macaques infected with a chimera of simian immunodeficiency virus containing reverse transcriptase from HIV type 1. Antimicrob Agents Chemother 2004;48:3483-90.
24. Nishimura Y, Igarashi T, Donau O, et al. Highly pathogenic SHIVs and SIVs target different CD4+ T cell subsets in rhesus monkeys, explaining their divergent clinical courses. Proc Natl Acad Sci USA 2004;101:12324-9.
25. Harouse J, Gettie A, Tan R, et al. Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs. Science 1999;284:816-9.
26. Feinberg M, Moore J. AIDS vaccine models: challenging challenge viruses. Nature Med 2002;8:207-10.
27. Lifson J, Martin M. One step forwards, one step back. Nature 2002;415:272-3.
28. Van Rompay K, Singh R, Marthas M. SIV as a model for AIDS drug studies; In: M. Bendinelli, S. C. Specter and H. Friedman, editors. Animal models of HIV disease and control. New York: Kluwer Academic/Plenum Publishers; 2005; in press.
29. Van Rompay K, Otsyula M, Marthas M, et al. Immediate zidovudine treatment protects simian immunodeficiency virus-infected newborn macaques against rapid onset of AIDS. Antimicrob Agents Chemother 1995;39:125-31.
30. McChesney M, Sawai E, Miller C. Simian immunodeficiency virus; In: R. Ahmed and I. Chen, editors. Persistent viral infections. New York: John Wiley & Sons, Ltd; 1998. p. 322-45.
31. Wingfield C, Booth J, Sheridan P, et al. SIV 4.0, performance characteristics of an exceptionally sensitive, quantitative assay for SIV RNA using branched DNA technology. 20th Annual Symposium on Nonhuman Primate Models for AIDS. 2002, Monterey, CA. Abstract 135.
32. Lifson J, Nowak M, Goldstein S, et al. The extent of early viral replication is a critical determinant of the natural history of simian immunodeficiency virus infection. J Virol 1997;71:9508-14.
33. Leutenegger C, Higgins J, Matthews T, et al. Real-time Taqman PCR as a specific and more sensitive alternative to the branched-chain DNA assay for quantitation of simian immunodeficiency virus RNA. AIDS Res Hum Retroviruses 2001;17:243-51.
34. Van Rompay K, Cherrington J, Marthas M, et al. 9-[2-(Phosphonomethoxy)propyl]adenine therapy of established simian immunodeficiency virus infection in infant rhesus macaques. Antimicrob Agents Chemother 1996;40:2586-91.
35. Van Rompay K, Singh R, Brignolo L, et al. The clinical benefits of tenofovir for simian immunodeficiency virus-infected macaques are larger than predicted by its effects on standard viral and immunological parameters. J Acquired Immune Defic Syndr 2004;36:900-14.
36. Tsai C, Follis K, Beck T, et al. Prevention of simian immunodeficiency virus infection in macaques by 9-(2-phosphonylmethoxypropyl)adenine (PMPA). Science 1995;270:1197-9.
37. Deeks S, Barditch-Crovo P, Lietman P, et al. Safety, pharmacokinetics and antiretroviral activity of intravenous 9-[2-(R)-(Phosphonomethoxy)propyl]adenine, a novel anti-HIV therapy, in HIV-infected adults. Antimicrob Agents Chemother 1998;42:2380-4.
38. Barditch-Crovo P, Deeks S, Collier A, et al. Phase I/II trial of the pharmacokinetics, safety, and antiretroviral activity of tenofovir disoproxil fumarate in HIV-1 infected adults. Antimicrob Agents Chemother 2001;45:2733-9.
39. Schooley R, Ruane P, Myers R, et al. Tenofovir DF in antiretroviral-experienced patients: results from a 48-week, randomized, double-blind study. AIDS 2002;16:1257-63.
40. Ha J, Nosbisch C, Conrad S, et al. Fetal toxicity of zidovudine (azidothymidine) in macaca nemestrina: preliminary observations. J Acquired Immune Defic Syndr 1994;7:154-7.
41. Lopez-Anaya A, Unadkat J, Schumann L, et al. Pharmacokinetics of zidovudine (Azidothymidine). III. Effect of pregnancy. J Acquir Immune Defic Syndr 1991;4:64-8.
42. Odineces A, Pereira C, Nosbisch C, et al. Prenatal and postpartum pharmacokinetics of stavudine (2′,3-pm-didehydro-3′-deoxythymidine) and didanosine (dideoxyinosine) in pigtailed macaques (Macaca nemestrina). Antimicrob Agents Chemother 1996;40:2423-5.
43. Pereira C, Nosbisch C, Baughman W, et al. Effect of zidovudine on transplacental pharmacokinetics of ddl in the pigtailed macaque (Macaca nemestrina). Antimicrob Agents Chemother 1995; 39:343-5.
44. Ravasco R, Unadkat J, Tsai C, et al. Pharmacokinetics of dideoxyinosine in pigtailed macaques (Macaca nemestrina) after intravenous and subcutaneous administration. J Acquired Immune Defic Syndr 1992;5:1016-8.
45. Tuntland T, Nosbisch C, Baughman W, et al. Mechanism and rate of placental transfer of zalcitabine (2-pm,3′ - dideoxycytidine) in Macaca nemestrina. Am J Obstet Gynecol 1996; 174:856-63.
46. Van Rompay K, Hamilton M, Kearney B, et al. Pharmacokinetics of tenofovir in breast milk of lactating rhesus macaques. Antimicrob Agents Chemother 2005;49:2093-4.
47. Van Rompay K, Brignolo L, Meyer D, et al. Biological effects of short-term and prolonged administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA; tenofovir) to newborn and infant rhesus macaques. Antimicrob Agents Chemother 2004;48:1469-87.
48. Grob P, Cao Y, Muchmore E, et al. Prophylaxis against HIV-1 infection in chimpanzees by nevirapine, a nonnucleoside inhibitor of reverse transcriptase. Nature Med 1997;3:665-70.
49. Van Rompay K, McChesney M, Aguirre N, et al. Two low doses of tenofovir protect newborn macaques against oral simian immunodeficiency virus infection. J Infect Dis 2001;184:429-38.
50. Miller C, Rosenberg Z, Bischofberger N. Use of topical PMPA to prevent vaginal transmission of SIV. Ninth International Conference on Antiviral Research. 1996, Fukushima, May 19-24.
51. Manson K, Wyand M, Miller C, et al. Effect of a cellulose acetate phtalate topical cream on vaginal transmission of simian immunodeficiency virus in rhesus monkeys. Antimicrob Agents Chemother 2000;44:3199-202.
52. Weber J, Nunn A, O'Connor T, et al. 'Chemical condoms' for the prevention of HIV infection: evaluation of novel agents against SHIV98.6PD in vitro and in vivo. AIDS 2001;15:1563-8.
53. Lederman M, Veazey R, Offord R, et al. Prevention of vaginal SHIV transmission in rhesus macaques through inhibition of CCR5. Science 2004;306:485-7.
54. Tsai C, Emau P, Jiang Y, et al. Cyanovirin-N inhibits AIDS virus infections in vaginal transmission models. AIDS Res Hum Retroviruses 2004;20:11-8.
55. Tsai C, Emau P, Jiang Y, et al. Cyanovirin-N gel as a topical microbicide prevents rectal transmission of SHIV89.6P in macaques. AIDS Res Hum Retroviruses 2003;19:535-41.
56. Wyand M, Manson K, Miller C, et al. Effect of 3-hydroxyphthaloyl-betalactoglobulin on vaginal transmission of simian immunodeficiency virus in rhesus monkeys. Antimicrob Agents Chemother 1999;43:978-80.
57. Wyand M. The use of SIV-infected rhesus monkeys for the preclinical evaluation of AIDS drugs and vaccines. AIDS Res Hum Retrovir 1992;8:349-56.
58. Fazely F, Haseltine W, Rodger R, et al. Postexposure chemoprophylaxis with ZDV or ZDV combined with interferon-α: failure after inoculating rhesus monkeys with a high dose of SIV. J Acquir Immune Defic Syndr 1991;4:1093-7.
59. Lundgren B, Bottiger D, Ljungdahl-Ståhle E, et al. Antiviral effects of 3′-fluorothymidine and 3′-azidothymidine in cynomolgus monkeys infected with simian immunodeficiency virus. J Acquir Immune Defic Syndr 1991;4:489-98.
60. McClure H, Anderson D, Ansari A, et al. Nonhuman primate models for evaluation of AIDS therapy. Ann N Y Acad Sci 1990; 616:287-98.
61. Black R. Animal studies of prophylaxis. Am J Med 1997;102 (5B):39-43.
62. Van Rompay K, Marthas M, Ramos R, et al. Simian immunodeficiency virus (SIV) infection of infant rhesus macaques as a model to test antiretroviral drug prophylaxis and therapy: oral 3′-azido-3′-deoxythymidine prevents SIV infection. Antimicrob Agents Chemother 1992;36:2381-6.
63. Van Rompay K, Marthas M, Lifson J, et al. Administration of 9-[2-(phosphonomethoxy)propyl]adenine (PMPA) for prevention of perinatal simian immunodeficiency virus infection in rhesus macaques. AIDS Res Hum Retroviruses 1998;14:761-73.
64. Van Rompay K, Berardi C, Aguirre N, et al. Two doses of PMPA protect newborn macaques against oral simian immunodeficiency virus infection. AIDS 1998;12:F79-F83.
65. Böttiger D, Putkonen P, Öberg B. Prevention of HIV-2 and SIV infections in cynomolgus macaques by prophylactic treatment with 3′-fluorothymidine. AIDS Res Hum Retrovir 1992;8:1235-8.
66. Böttiger D, Vrang L, Öberg B. Influence of the infectious dose of simian immunodeficiency virus on the acute infection in cynomolgus monkeys and on the affect of treatment with 3′-fluorothymidine. Antivir Chem Chemother 1992;3:267-71.
67. Tsai C, Follis K, Sabo A, et al. Preexposure prophylaxis with 9-(-2-phosphonylmethoxyethyl)adenine against simian immunodeficiency virus infection in macaques. J Infect Dis 1994;169:260-6.
68. Subbarao S, Otten R, Ramos A, et al. Chemoprophylaxis with oral tenofovir disoproxil fumarate (TDF) delays but does not prevent infection in rhesus macaques given repeated rectal challenges of SHIV. 12th Conference on Retroviruses and Opportunistic Infections. 2005, Boston, Massachusetts. Abstract 136LB.
69. Van Rompay K, Lawson J, Colón R, et al. Oral tenofovir DF protects infant macaques against infection following repeated low-dose oral exposure to virulent simian immunodeficiency virus. XV International AIDS Conference. 2004, Bangkok. (LbOrB10).
70. Böttiger D, Johansson N, Samuelsson B, et al. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre- and postexposure administration of BEA-005. AIDS 1997;11:157-62.
71. Otten R, Smith D, Adams D, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (HIV type 2). J Virol 2000;74:9771-5.
72. Tsai C, Emau P, Follis K, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl)adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol 1998;72:4265-73.
73. Centers for Disease Control and Prevention. Update: provisional Public Health Service recommendations for chemoprophylaxis after occupational exposure to HIV. MMWR 1996;45:468-72.
74. Centers for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States: recommendations from the U.S. Department of Health and Human Services. MMWR 2005;54:1-19.
75. Puro V, Calcagno G, Anselmo M, et al. Transient detection of plasma HIV-1 RNA during postexposure prophylaxis. Infect Control Hosp Epidemiol 2000;21:529-31.
76. AIDS Vaccine Advocacy Coalition. Will a pill a day prevent HIV? Anticipating the results of the tenofovir "PREP" trials. (www.avac.org). March 2005
77. Gaillard P, Fowler M, Dabis F, et al. Use of antiretroviral drugs to prevent HIV-1 transmission through breastfeeding: from animal studies to randomized clinical trials. J Acquired Immune Defic Syndr 2004;35:178-87.
78. Connor E, Sperling R, Gelber R, et al. Reduction of maternal-infant transmission of HIV type 1 with zidovudine treatment. N Engl J Med 1994;331:1173-80.
79. Guay L, Musoke P, Fleming T, et al. Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: HIVNET 012 randomized trial. Lancet 1999;354:795-802.
80. Eshleman S, Mracna M, Guay L, et al. Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET012). AIDS 2001; 15:1951-7.
81. Martin L, Murphey-Corb M, Soike K, et al. Effects of initiation of 3′-azido-3′-deoxythymidine treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J Infect Dis 1993;168:825-35.
82. Tsai C, Follis K, Grant R, et al. Effect of dosing frequency on ZDV prophylaxis in macaques infected with simian immunodeficiency virus. J Acquired Immune Defic Syndr 1993;6:1086-92.
83. Joag S, Li Z, Foresman L, et al. Early treatment with 9-(2-phosphonylmethoxyethyl) adenine reduces virus burdens for a prolonged period in SIV-infected rhesus macaques. AIDS Res Hum Retroviruses 1997;13:241-6.
84. Le Grand R, Clayette P, Noack O, et al. An animal model for anti-lentiviral therapy: effect of zidovudine on viral load during acute infection after exposure of macaques to simian immunodeficiency virus. AIDS Res Hum Retroviruses 1994;10:1279-87.
85. Le Grand R, Vaslin B, Larghero J, et al. Post-exposure prophylaxis with highly active antiretroviral therapy could not protect macaques from infection with SIV/HIV chimera. AIDS 2000;14:1864-6.
86. Van Rompay K, Dailey P, Tarara R, et al. Early short-term 9-[2-(phosphonomethoxy)propyl] adenine (PMPA) treatment favorably alters subsequent disease course in simian immunodeficiency virus-infected newborn rhesus macaques. J Virol 1999;73:2947-55.
87. Watson A, McClure J, Ranchalis J, et al. Early postinfection antiviral treatment reduces viral load and prevents CD4+ cell decline in HIV type 2-infected macaques. AIDS Res Hum Retroviruses 1997; 13:1375-81.
88. Rausch D, Heyes M, Murray E, et al. Zidovudine treatment prolongs survival and decreases virus load in the central nervous system of rhesus macaques infected perinatally with simian immunodeficiency virus. J Infect Dis 1995;172:59-69.
89. Rosenwirth B, ten Haaft P, Bogers W, et al. Antiretroviral therapy during primary immunodeficiency virus infection can induce persistent suppression of virus load and protection from heterologous challenge in rhesus macaques. J Virol 2000;74:1704-11.
90. Smith M, Foresman L, Lopez G, et al. Lasting effects of transient postinoculation tenofovir [9-R-(2-phosphonomethoxypropyl)adenine] treatment of SHIVKU2 infection of rhesus macaques. Virology 2000;277:306-15.
91. Hodge S, De Rosayro J, Glenn A, et al. Postinoculation PMPA treatment, but not preinoculation immunomodulatory therapy, protects against development of acute disease induced by the unique simian immunodeficiency virus SIVsmmPBj. J Virol 1999; 73:8630-9.
92. Lifson J, Rossio J, Arnaout R, et al. Containment of simian immunodeficiency virus infection: cellular immune responses and protection from rechallenge following transient postinoculation antiretroviral treatment. J Virol 2000;74:2584-93.
93. Lori F, Gallo R, Malykh A, et al. Didanosine but not high doses of hydroxyurea rescue pigtail macaque from a lethal dose of SIVsmmpbj14. AIDS Res Hum Retroviruses 1997;13:1083-8.
94. Spring M, Stahl-Hennig C, Stolte N, et al. Enhanced cellular immune responses and reduced CD8+ lymphocytes apoptosis in acutely SIV-infected rhesus macaques after short-term antiretroviral treatment. Virology 2001;279:221-31.
95. Hecht F, Wang L, Collier A, et al. Outcomes of HAART for acute/early HIV-1 infection after treatment discontinuation. Program and abstracts of the 12th Conference on Retroviruses and Opportunistic Infections, February 22-25. 2005, Boston, Massachusetts. Abstract 568.
96. Berrey M, Schacker T, Collier A, et al. Treatment of primary HIV type 1 infection with potent antiretroviral therapy reduces frequency of rapid progression to AIDS. J Infect Dis 2001;183:1466-75.
97. Kinloch-de Loës S, Hirschel B, Hoen B, et al. A controlled trial of zidovudine in primary HIV infection. N Engl J Med 1995;333:408-13.
98. Lafeuillade A, Poggi C, Tamalet C, et al. Effects of a combination of zidovudine, didanosine, and lamivudine on primary HIV type 1 infection. J Infect Dis 1997;175:1051-5.
99. Rosenberg E, Altfeld M, Poon S, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000;407:523-6.
100. Kassutto S, Rosenberg ES. Primary HIV type 1 infection. Clin Infect Dis 2004;38:1447-53.
101. Igarashi T, Brown C, Endo Y, et al. Macrophage are the principal reservoir and sustain high virus loads in rhesus macaques after the depletion of CD4+ T cells by a highly pathogenic simian immunodeficiency virus/HIV type 1 chimera (SHIV): implications for HIV-1 infections of humans. Proc Natl Acad Sci USA 2001;98:658-63.
102. Hel Z, Venzon D, Poudyal M, et al. Viremia control following antiretroviral treatment and therapeutic immunization during primary SIV251 infection of macaques. Nature Med 2000;6:1140-6.
103. Lori F, Lisziewicz J. Structured treatment interruptions for the management of HIV infection. JAMA 2001;286:2981-7.
104. Markowitz M, Jin X, Hurley A, et al. Discontinuation of antiretroviral therapy commenced early during the course of human HIV type 1 infection, with or without adjunctive vaccination. J Infect Dis 2002;186:634-43.
105. Daar E, Bai J, Hausner M, et al. Acute HIV syndrome after discontinuation of antiretroviral therapy in a patient treated before seroconversion. Ann Int Med 1998;128:827-9.
106. Böttiger D, Ståhle L, Li S, et al. Long-term tolerance and efficacy of 3′-azido-thymidine and 3′-fluorothymidine treatment of asymptomatic monkeys infected with simian immunodeficiency virus. Antimicrob Agents Chemother 1992;36:1770-2.
107. Van Rompay K, Greenier J, Marthas M, et al. A zidovudine-resistant simian immunodeficiency virus mutant with a Q151M mutation in reverse transcriptase causes AIDS in newborn macaques. Antimicrob Agents Chemother 1997;41:278-83.
108. Van Rompay K, Matthews T, Higgins J, et al. Virulence and reduced fitness of simian immunodeficiency virus with the M184V mutation in reverse transcriptase. J Virol 2002;76:6083-92.
109. Tsai C, Follis K, Beck T, et al. Effects of (R)-9-(2-phosphonylmethoxypropyl) adenine monotherapy on chronic SIV infection. AIDS Res Hum Retroviruses 1997;13:707-12.
110. Tsai C, Follis K, Sabo A, et al. Efficacy of 9-(2-phosphonylmethoxyethyl)adenine treatment against chronic simian immunodeficiency virus infection in macaques. J Infect Dis 1995;171:1338-43.
111. Nowak M, Lloyd A, Vasquez G, et al. Viral dynamics of primary viremia and antiretroviral therapy in simian immunodeficiency virus infection. J Virol 1997;71:7518-25.
112. Silvera P, Racz P, Racz K, et al. Effect of PMPA and PMEA on the kinetics of viral load in simian immunodeficiency virus-infected macaques. AIDS Res Hum Retroviruses 2000;16:791-800.
113. Van Rompay K, Singh R, Pahar B, et al. CD8+ cell-mediated suppression of virulent simian immunodeficiency virus during tenofovir treatment. J Virol 2004;78:5324-37.
114. Magierowska M, Bernardin F, Garg S, et al. Highly uneven distribution of PMPA selected SIV drug resistance genotypes in different anatomical sites of rhesus macaques. J Virol 2004;78:2434-44.
115. Smit-McBride Z, Mattapallil J, Villinger F, et al. Intracellular cytokine expression in the CD4+ and CD8+ T cells from intestinal mucosa of simian immunodeficiency virus infected macaques. J Med Primatol 1998;27:129-40.
116. Veazy R, DeMaria M, Chalifoux L, et al. Gastrointestinal tract as a major site of CD4+ T cell depletion and viral replication in SIV infection. Science 1998; 280:427-31.
117. Heise C, Miller C, Lackner A, et al. Primary acute simian immunodeficiency virus infection of intestinal lymphoid tissue is associated with gastrointestinal dysfunction. J Infect Dis 1994;169:1116-20.
118. Mattapallil J, Smit-McBride Z, Dailey P, et al. Activated memory CD4+ T helper cells repopulate the intestine early following antiretroviral therapy of simian immunodeficiency virus-infected rhesus macaques but exhibit a decreased potential to produce interleukin-2. J Virol 1999;73:6661-9.
119. George M, Reay E, Sankaran S, et al. Early antiretroviral therapy for simian immunodeficiency virus infection leads to mucosal CD4+ T-cell restoration and enhanced gene expression regulating mucosal repair and regeneration. J Virol 2005;79:2709-19.
120. Shen Y, Shen L, Sehgal P, et al. Antiretroviral agents restore mycobacterium-specific T-cell immune responses and facilitate controlling a fatal tuberculosis-like disease in macaques coinfected with simian immunodeficiency virus and Mycobacterium bovis BCG. J Virol 2001;75:8690-6.
121. Shen A, Zink M, Mankowski J, et al. Resting CD4+ T lymphocytes but not thymocytes provide a latent viral reservoir in a simian immunodeficiency virus-Macaca nemestrina model of HIV type 1 infected patients on highly active antiretroviral therapy. J Virol 2003;77:4938-49.
122. North T, Van Rompay K, Higgins J, et al. Suppression of virus load by highly active antiretroviral therapy in rhesus macaques infected with a recombinant simian immunodeficiency virus containing reverse transcriptase from HIV type 1. J Virol 2005;79:7349-54.
123. Lori F, Lewis M, Xu J, et al. Control of SIV rebound through structured treatment interruptions during early infection. Science 2000;290:1591-3.
124. Villinger F, Brice G, Mayne A, et al. Adoptive transfer of simian immunodeficiency virus (SIV) naive autologous CD4+ T cells to macaques chronically infected with SIV is sufficient to induce long-term nonprogressor status. Blood 2002;99:590-9.
125. Hel Z, Nacsa J, Kelsall B, et al. Impairment of gag-specific CD8+ T-cell function in mucosal and systemic compartments of simian immunodeficiency virus mac251-and simian-human immunodeficiency virus KU2-infected macaques. J Virol 2001;75:11483-95.
126. Tryniszewska E, Nacsa J, Lewis M, et al. Vaccination of macaques with long-standing SIVmac251 infection lowers the viral set point after cessation of antiretroviral therapy. J Immunol 2002;169:5347-57.
127. Hel Z, Nacsa J, Tsai W, et al. Equivalent immunogenicity of the highly attenuated poxvirus-based ALVAC-SIV and NYVAC-SIV vaccine candidates in SIVmac251-infected macaques. Virology 2002;304:125-34.
128. Nacsa J, Stanton J, Kunstman K, et al. Emergence of cytotoxic T lymphocyte escape mutants following antiretroviral treatment suspension in rhesus macaques infected with SIVmac251. Virology 2003;305:210-8.
129. Boyer J, Nath B, Schumann K, et al. IL-4 increases simian immunodeficiency virus replication despite enhanced SIV immune responses in infected rhesus macaques. Int J Parasitol 2002;32:543-50.
130. Lisziewicz J, Trocio J, Xu J, et al. Control of viral rebound through therapeutic immunization with DermaVir. AIDS 2005;19:35-43.
131. Richman D. HIV chemotherapy. Nature 2001;410:995-1001.
132. Bangsberg D, Moss A, Deeks S. Paradoxes of adherence and drug resistance to HIV antiretroviral therapy. J Antimicrob Chemother 2004;53:696-9.
133. Darby G, Larder B. The clinical significance of antiviral drug resistance. Res Virol 1992;143:116-20.
134. Richman D. The clinical significance of drug-resistant mutants of HIV. Res Virol 1992;143:130-1.
135. Richman D. Resistance, drug failure, and disease progression. AIDS Res Hum Retroviruses 1994;10:901-5.
136. Deeks S, Hoh R, Grant R, et al. CD4+ T cell kinetics and activation in HIV-Infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy. J Infect Dis 2002; 185:315-23.
137. Deeks S, Barbour J, Martin J, et al. Sustained CD4+ T cell response after virologic failure of protease inhibitor-based regimens in patients with HIV infection. J Infect Dis 2000;181:946-53.
138. Barbour J, Wrin T, Grant R, et al. Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in HIV-infected adults. J Virol 2002;76:11104-12.
139. Monpoux F, Tricoire J, Lalande M, et al. Treatment interruption for virologic failure or as sparing regimen in children with chronic HIV-1 infection. AIDS 2004;18:2401-9.
140. Bélec L, Piketty C, Si-Mohamed A, et al. High levels of drug-resistant HIV variants in patients exhibiting increasing CD4+ T counts despite virologic failure of protease inhibitor-containing antiretroviral combination therapy. J Infect Dis 2000;181:1808-12.
141. Miller V, Phillips A, Clotet B, et al. Association of virus load, CD4 cell count, and treatment with clinical progression in HIV-infected patients with very low CD4 cell counts. J Infect Dis 2002; 186:189-97.
142. Mezzaroma I, Carlesimo M, Pinter E, et al. Clinical and immunologic responses without decrease in virus load in patients after 24 months of highly active antiretroviral therapy. Clin Infect Dis 1999; 29:1423-30.
143. Deeks S, Martin J, Sinclair E, et al. Strong cell-mediated immune responses are associated with the maintenance of low-level viremia in antiretroviral-treated individuals with drug-resistant HIV type 1. J Infect Dis 2004;189:312-21.
144. Deeks S, Wrin T, Liegler T, et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-80.
145. Deeks S. Durable HIV treatment benefit despite low-level viremia. Reassessing definitions of success or failure. JAMA 2001; 286:224-6.
146. Hunt P, Martin J, Sinclear E, et al. Drug-resistant phenotype is associated with decreased in vivo T-cell activation independent of changes in viral replication among patients discontinuing antiretroviral therapy. Antiviral Therapy 2003;8:S82.
147. Borda J, Alvarez X, Kondova I, et al. Cell tropism of simian immunodeficiency virus in culture is not predictive of in vivo tropism or pathogenesis. Amer J Pathol 2004;165:2111-22.
148. Kestler H, III, Ringler D, Mori K, et al, Importance of the nef gene for maintenance of high virus loads and for development of AIDS. Cell 1991;65:651-62.
149. Lohman B, McChesney M, Miller C, et al. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J Virol 1994;68:7021-9.
150. Hirsch M, Brun-Vezinet F, Clotet B, et al. Antiretroviral drug resistance testing in adults infected with HIV type 1: 2003 recommendations of an International AIDS Society-USA Panel. Clin Infect Dis 2003;37:113-28.
151. Gandhi R, Wurcel A, Rosenberg E, et al. Progressive reversion of HIV type 1 resistance mutations in vivo after transmission of a multiply drug-resistant virus. Clin Infect Dis 2003;37:1693-8.
152. Izopet J, Souyris C, Hance A, et al. Evolution of HIV type 1 populations after resumption of therapy following treatment interruption and shift in resistance genotype. J Infect Dis 2002; 185:1506-10.
153. Cherry E, Slater M, Salomon H, et al, Mutations at codon 184 in simian immunodeficiency virus reverse transcriptase confer resistance to the (-) enantiomer of 2′,3′-dideoxy-thiacytidine. Antimicrob Agents Chemother 1997;41:2763-5.
154. Murry J, Higgins J, Matthews T, et al. Reversion of the M184V mutation in simian immunodeficiency virus reverse transcriptase is selected by tenofovir, even in the presence of lamivudine. J Virol 2003;77:1120-30.
155. Schmit J, Cogniaux J, Hermans P, et al. Multiple drug Resistance to nucleoside analogues and non-nucleoside reverse transcriptase inhibitors in an efficiently replicating HIV-1 patient strain. J Infect Dis 1996;174:962-8.
156. Shafer R, Winters M, Iversen A, et al. Genotypic and phenotypic changes during culture of a multinucleoside-resistant HIV type 1 strain in the presence and absence of additional reverse transcriptase inhibitors. Antimicrob Agents Chemother 1996;40:2887-90.
157. Colson P, Henry M, Tivoli N, et al. Polymorphism and drug-selected mutations in the reverse transcriptase gene of HIV-2 from patients living in southern France. Antiviral Therapy 2003;8:S161.
158. Descamps D, Damond F, Matheron S, et al. High frequency of selection of the Q151M mutation in HIV-2-infected patients receiving nucleoside reverse transcriptase inhibitor-containing regimen. Antiviral Therapy 2003;8:S162.
159. Newstein M, Desrosiers R. Effects of reverse-transcriptase mutations M184V and E89G on simian immunodeficiency virus in rhesus monkeys. J Infect Dis 2001;184:1262-7.
160. Ruane P, Luber A. K65R-Associated Virologic Failure in HIV-Infected Patients Receiving Tenofovir-Containing Triple Nucleoside/Nucleotide Reverse Transcriptase Inhibitor Regimens. MedGenMed 2004;6:31.
161. Valer L, Martín-Carbonero L, de Mendoza C, et al. Predictors of selection of K65R: tenofovir use and lack of thymidine analogue mutations. AIDS 2004;18:2094-6.
162. Margot N, Isaacson E, McGowan I, et al. Extended treatment with tenofovir disoproxil fumarate in treatment-experienced HIV-1-infected patients: genotypic, phenotypic, and rebound analyses. J Acquired Immune Defic Syndr 2003;33:15-21.
163. Van Rompay K, Cherrington J, Marthas M, et al. 9-[2-(Phosphonomethoxy)propyl]adenine (PMPA) therapy prolongs survival of infant macaques inoculated with simian immunodeficiency virus with reduced susceptibility to PMPA. Antimicrob Agents Chemother 1999;43:802-12.
164. Perelson A. Modelling viral and immune system dynamics. Nature Immunology Reviews 2002;2:28-36.
165. Wodarz D, Nowak M. Mathematical models of HIV pathogenesis and treatment. Bioessays 2002;24:1178-87.
166. Bonhoeffer S, May R, Shaw G, et al. Virus dynamics and drug therapy. Proc Natl Acad Sci USA 1997;94:6971-6.
167. Buseyne F, Lechenadec J, Burgard M, et al. Gag-specific memory CTL responses and antiretroviral drugs act in synergy to control HIV-1 replication in infected children. 11th Conference on Retroviruses and Opportunistic Infections. 2004, San Francisco. Abstract 217.
168. Alatrakchi N, Duvivier C, Costagliola D, et al. Persistent low viral load on antiretroviral therapy is associated with T cell-mediated control of HIV replication. AIDS 2005;119:25-33.
169. Cohen Stuart J, Wensing A, Kovacs C, et al. Transient relapses ("blips") of plasma HIV RNA levels during HAART are associated with drug resistance. J Acquir Immune Defic Syndr 2001; 28:105-13.
170. Di Mascio M, Markowitz M, Louie M, et al. Viral blip dynamics during highly active antiretroviral therapy. J Virol 2003;77:12165-72.
171. Blankson J, Persaud D, Siliciano R. The challenge of viral reservoirs in HIV-1 infection. Annu Rev Med 2002;53:557-93.
172. McKay P, Barouch D, Schmitz J, et al. Global dysfunction of CD4 T-lymphocyte cytokine expression in simian-human immunodeficiency virus/SIV-infected monkeys is prevented by vaccination. J Virol 2003;77:4695-702.
173. Zimmer M, Larregina A, Castillo C. et al. Disrupted homeostasis of Langerhans cells and interdigitating dendritic cells in monkeys with AIDS. Blood 2002; 99:2859-68.
174. Kaech S and Ahmed R. CD8 T cells remember with a little help. Science 2003;300:263-5.
175. Lieberman J, Shankar P, Manjunath N, et al. Dressed to kill? A review of why antiviral CD8 T lymphocytes fail to prevent progressive immunodeficiency in HIV-1 infection. Blood 2001;98:1667-77.
176. McMichael A, Rowland-Jones S. Cellular immune responses to HIV. Nature 2001;410:980-7.
177. Ghaffari G, Passalacqua D, Caicedo J, et al. Two-year clinical and immune outcomes in HIV-infected children who reconstitute CD4 T cells without control of viral replication after combination antiretroviral therapy. Pediatrics 2004;114:e604-11.
178. Huang W, De Gruttola V, Fischl M, et al. Patterns of plasma HIV type 1 RNA response to antiretroviral therapy. J Infect Dis 2001; 183:1455-65.
179. Haverkamp M, Smit M, Weersink A, et al. The effect of lamivudine on the replication of hepatitis B virus in HIV-infected patients depends on the host immune status (CD4 cell count). AIDS 2003;17:1572-4.
180. Abel K, Alegria-Hartman M, Zanotto K, et al. Anatomic site and immune function correlate with relative cytokine mRNA expression levels in lymphoid tissues of normal rhesus macaques. Cytokine 2001;16:191-204.
181. Altfeld M, van Lunzen J, Frahm N, et al. Expansion of pre-existing, lymph node-localized CD8+ T cells during supervised treatment interruptions in chronic HIV-1 infection. J Clin Invest 2002;109:837-43.
182. Pantaleo G, Koup R. Correlates of immune protection in HIV-1 infection: what we know, what we don't know, what we should know. Nat Med 2004;10:806-10.
183. Betts M, Ambrozak D, Douelk D, et al. Analysis of total HIV-specific CD4+ and CD8+ T-cell responses: relationship to viral load in untreated HIV infection. J Virol 2001;75:11983-91.
184. Van Rompay K, Abel K, Lawson J, et al. Attenuated poxvirus-based SIV vaccines given in infancy partially protect infant and juvenile macaques against repeated oral challenge with virulent SIV. J Acquired Immune Defic Syndr 2005;38:124-34.
185. Frost S, Nijhuis M, Schuurman R, et al. Evolution of lamivudine resistance in HIV type 1-infected individuals: the relative roles of drift and selection. J Virol 2000;74:6262-8.
186. Deeks S, Barbour J, Grant R, et al. Duration and predictors of CD4 T-cell gains in patients who continue combination therapy despite detectable plasma viremia. AIDS 2002;16:201-7.
187. Renaud M, Katlama C, Mallet A, et al. Determinants of paradoxical CD4 cell reconstitution after protease inhibitor-containing antiretroviral regimen. AIDS 1999;13:669-76.
188. Ledergerber B, Egger M, Opravil M, et al. Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort study. Lancet 1999;353:863-8.
189. Sloand E, Kumar P, Kim S, et al. HIV type 1 protease inhibitor modulates activation of peripheral blood CD4+ T cells and decreases their susceptibility to apoptosis in vitro and in vivo. Blood 1999;94:1021-7.
190. Price D, Scullard G, Oxenius A, et al. Discordant outcomes following failure of antiretroviral therapy are associated with substantial differences in HIV-specific cellular immunity. J Virol 2003;77:6041-9.
191. Atzori C, Angeli E, Mainini A, et al. In vitro activity of HIV protease inhibitors against pneumocystis carinii. J Infect Dis 2000: 181:1629-34.
192. Cassone A, Tacconelli E, De Bernardis F, et al. Antiretroviral therapy with protease inhibitors has an early, immune reconstitution-independent beneficial effect on Candida virulence and oral candidiasis in HIV-infected subjects. J Infect Dis 2002;185:188-95.
193. Zídek Z, Frankova D, Holy A. Activation by 9-(R)-[2-(phosphonomethoxy)propyl] adenine of chemokine (RANTES, macrophage inflammatory protein 1α) and cytokine (tumor necrosis factor alpha, interleukin-10 [IL-10], IL-1β) production. Antimicrob Agents Chemother 2001;45:3381-6.
194. Van Rompay K, Marthas M, Bischofberger N. Tenofovir primes rhesus macaque cells in vitro for enhanced interleukin-12 secretion. Antiviral Res 2004;63:133-8.
195. Lu W, Wu X, Lu Y, et al. Therapeutic dendritic-cell vaccine for simian AIDS. Nature Med 2003;9:27-32.
196. Arnaout R, Nowak M, Wodarz D. HIV-1 dynamics revisited: biphasic decay by cytotoxic T lymphocyte killing? Proc R Soc Lond 2000;267:1347-54.